ISU106 (nivolumab biosimilar) / R-Pharm, ISU Abxis - LARVOL DELTA

Isu Abix records highest sales and profits in the first half of the year… “Thanks to increased sales from technology transfer” [Google translation] (Nate) - "Isu Abxis...recorded its best performance since its establishment in the first half of the year with sales of KRW 30.9 billion and operating profit of KRW 8 billion....Sales related to the technology transfer of ISU104 and ISU106, worth KRW 4.8 billion, also contributed significantly. Isu Abxis transferred the technology of ISU104 to a U.S. anticancer drug development company in June, and of the initial contract deposit of USD 3 million (approximately KRW 4.2 billion), USD 2 million (approximately KRW 2.8 billion) was recognized first in the second quarter, as per the contract."

Sales • Breast Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • Oncology • Solid Tumor